(ANSA) - ROME, DECEMBER 14 - A molecular test is on the way that can detect and differentiate between the SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) with a single swab.
This was announced by the Abbott company, which developed it, according to which the test has just obtained the Ce mark.
The Alinity m Resp-4-Plex test, it reads, can be performed with a single nasopharyngeal swab collected by a healthcare professional in people with signs and symptoms of respiratory tract infection, and will be performed on the Alinity m system, the most advanced laboratory analyzer for Abbott's molecular biology for high test volumes. Alinity mutilates Polymerase Chain Reaction (PCR) technology. To help combat the pandemic, Abbott has accelerated the deployment of the Alinity m system to hospitals, university centers and laboratories, all crucial facilities for patient care. "While health care workers are at the forefront of addressing the Covid-19 pandemic, they must now also cope with the additional influx from seasonal flu," said Andrea Wainer, Executive Vice President, Rapid and Molecular Diagnostics, Abbott. "Abbott has made every effort to provide tests for Covid-19 in as many contexts as possible, and this new test will enable rapid and efficient diagnosis and triage of patients with respiratory symptoms so that they can receive the most appropriate care." (HANDLE).